Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Pim-1 phosphorylates the DNA binding domain of c-Myb.

Winn LM, Lei W, Ness SA.

Cell Cycle. 2003 May-Jun;2(3):258-62.

PMID:
12734436
2.

Differential sensitivity of v-Myb and c-Myb to Wnt-1-induced protein degradation.

Kanei-Ishii C, Nomura T, Tanikawa J, Ichikawa-Iwata E, Ishii S.

J Biol Chem. 2004 Oct 22;279(43):44582-9. Epub 2004 Aug 11.

3.

Differential regulation of c-Myb-induced transcription activation by a phosphorylation site in the negative regulatory domain.

Miglarese MR, Richardson AF, Aziz N, Bender TP.

J Biol Chem. 1996 Sep 13;271(37):22697-705.

4.

Casein kinase II phosphorylation site mutations in c-Myb affect DNA binding and transcriptional cooperativity with NF-M.

Oelgeschläger M, Krieg J, Lüscher-Firzlaff JM, Lüscher B.

Mol Cell Biol. 1995 Nov;15(11):5966-74.

5.
6.

c-Myb and v-Myb are differentially phosphorylated by p42mapk in vitro.

Aziz N, Wu J, Dubendorff JW, Lipsick JS, Sturgill TW, Bender TP.

Oncogene. 1993 Aug;8(8):2259-65.

PMID:
8336948
7.

HIPK1 interacts with c-Myb and modulates its activity through phosphorylation.

Matre V, Nordgård O, Alm-Kristiansen AH, Ledsaak M, Gabrielsen OS.

Biochem Biophys Res Commun. 2009 Oct 9;388(1):150-4. doi: 10.1016/j.bbrc.2009.07.139. Epub 2009 Jul 30.

PMID:
19646965
8.

The effects of benzene and the metabolites phenol and catechol on c-Myb and Pim-1 signaling in HD3 cells.

Wan J, Winn LM.

Toxicol Appl Pharmacol. 2004 Dec 1;201(2):194-201.

PMID:
15541759
9.

Regulation of c-Myb through protein phosphorylation and leucine zipper interactions.

Ramsay RG, Morrice N, Van Eeden P, Kanagasundaram V, Nomura T, De Blaquiere J, Ishii S, Wettenhall R.

Oncogene. 1995 Nov 16;11(10):2113-20.

PMID:
7478531
10.

Myb protein specificity: evidence of a context-specific transcription factor code.

Ness SA.

Blood Cells Mol Dis. 2003 Sep-Oct;31(2):192-200.

PMID:
12972026
11.

Functional analysis of phosphorylation at serine 532 of human c-Myb by MAP kinase.

Vorbrueggen G, Lovrić J, Moelling K.

Biol Chem. 1996 Nov;377(11):721-30.

PMID:
8960373
12.

The highly conserved DNA-binding domains of A-, B- and c-Myb differ with respect to DNA-binding, phosphorylation and redox properties.

Bergholtz S, Andersen TO, Andersson KB, Borrebaek J, Lüscher B, Gabrielsen OS.

Nucleic Acids Res. 2001 Sep 1;29(17):3546-56.

13.
14.
15.

Myb-induced transformation.

Wolff L.

Crit Rev Oncog. 1996;7(3-4):245-60. Review.

PMID:
9258605
16.

Myb DNA binding inhibited by phosphorylation at a site deleted during oncogenic activation.

Lüscher B, Christenson E, Litchfield DW, Krebs EG, Eisenman RN.

Nature. 1990 Apr 5;344(6266):517-22.

PMID:
2157164
17.

Histone H3 tail positioning and acetylation by the c-Myb but not the v-Myb DNA-binding SANT domain.

Mo X, Kowenz-Leutz E, Laumonnier Y, Xu H, Leutz A.

Genes Dev. 2005 Oct 15;19(20):2447-57. Epub 2005 Sep 29.

18.
19.

Expression patterns of c-myb and of v-myb induced myeloid-1 (mim-1) gene during the development of the chick embryo.

Quéva C, Ness SA, Grässer FA, Graf T, Vandenbunder B, Stéhelin D.

Development. 1992 Jan;114(1):125-33.

20.

Mitotic cyclins stimulate the activity of c-Myb-like factors for transactivation of G2/M phase-specific genes in tobacco.

Araki S, Ito M, Soyano T, Nishihama R, Machida Y.

J Biol Chem. 2004 Jul 30;279(31):32979-88. Epub 2004 Jun 1.

Supplemental Content

Support Center